drugset / Trial / NCT00104884
FR901228 in Treating Patients With Unresectable Stage III or Stage IV Malignant Melanoma
Phase 2
Terminated
4 enrolled
ECOG-ACRIN Cancer Research Group
National Cancer Institute (NCI) · collab
NaSingle-groupOpen-labelTreatment
Summary
RATIONALE: Drugs used in chemotherapy, such as FR901228, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. PURPOSE: This phase II trial is studying how well FR901228 works in treating patients with unresectable stage III or stage IV malignant melanoma.
Timeline
- Start
- 2005-10-04
- Primary completion
- 2006-05
- Completion
- 2009-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Romidepsin | Peptide | 13 mg/m2 | Intravenous |